GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Laboratory Corp of America Holdings (NYSE:LH) » Definitions » Enterprise Value

Laboratory of America Holdings (Laboratory of America Holdings) Enterprise Value : $22,576 Mil (As of Apr. 26, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Laboratory of America Holdings Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Laboratory of America Holdings's Enterprise Value is $22,576 Mil. Laboratory of America Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $790 Mil. Therefore, Laboratory of America Holdings's EV-to-EBIT ratio for today is 28.58.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Laboratory of America Holdings's Enterprise Value is $22,576 Mil. Laboratory of America Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $1,356 Mil. Therefore, Laboratory of America Holdings's EV-to-EBITDA ratio for today is 16.65.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Laboratory of America Holdings's Enterprise Value is $22,576 Mil. Laboratory of America Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $12,300 Mil. Therefore, Laboratory of America Holdings's EV-to-Revenue ratio for today is 1.84.


Laboratory of America Holdings Enterprise Value Historical Data

The historical data trend for Laboratory of America Holdings's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratory of America Holdings Enterprise Value Chart

Laboratory of America Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20,883.83 22,470.02 29,978.50 23,771.60 24,502.53

Laboratory of America Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23,363.55 22,672.82 22,690.55 24,502.53 24,387.96

Competitive Comparison of Laboratory of America Holdings's Enterprise Value

For the Diagnostics & Research subindustry, Laboratory of America Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratory of America Holdings's Enterprise Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Laboratory of America Holdings's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Laboratory of America Holdings's Enterprise Value falls into.



Laboratory of America Holdings Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Laboratory of America Holdings's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Laboratory of America Holdings's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratory of America Holdings  (NYSE:LH) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Laboratory of America Holdings's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=22575.782/789.8
=28.58

Laboratory of America Holdings's current Enterprise Value is $22,576 Mil.
Laboratory of America Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $790 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Laboratory of America Holdings's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=22575.782/1355.7
=16.65

Laboratory of America Holdings's current Enterprise Value is $22,576 Mil.
Laboratory of America Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,356 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Laboratory of America Holdings's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=22575.782/12300.4
=1.84

Laboratory of America Holdings's current Enterprise Value is $22,576 Mil.
Laboratory of America Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12,300 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratory of America Holdings Enterprise Value Related Terms

Thank you for viewing the detailed overview of Laboratory of America Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratory of America Holdings (Laboratory of America Holdings) Business Description

Traded in Other Exchanges
Address
358 South Main Street, Burlington, NC, USA, 27215
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Executives
Peter J Wilkinson officer: SVP, Chief Accounting Officer C/O PHARMACEUTICAL PRODUCT DEVELOPMENT, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Kerrii B Anderson director WENDY'S INTERNATIONAL, INC, 4288 WEST DUBLIN-GRANVILLE RD., DUBLIN OH 43017
Van Der Vaart Sandra D officer: SVP, Global General Counsel 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Paul Rothman director 6 MEADOW ROAD, BALTIMORE MD 21212
Paul R Kirchgraber officer: CEO, Covance Drug Development 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark S Schroeder officer: EVP, President-Diagnostics Lab 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Megan D. Bailey officer: EVP, Chief Strategy Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Jonathan P. Divincenzo officer: EVP, Pres, Central Labs & Intl 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Anita Z Graham officer: EVP, CHRO C/O THE ADT CORPORATION, 1501 YAMATO ROAD, BOCA RATON FL 33431
Thomas Pike officer: Pres & CEO Clinical Business C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Kirsten Marie Kliphouse director 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg officer: Chief Financial Officer, EVP P O BOX 1017, CHARLOTTE NC 28201-1017
Brian J Caveney officer: SVP, Chief Medical Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215
R Sanders Williams director DUKE UNIVERSITY SCHOOL OF MEDICINE, TRENT DRIVE, DURHAM NC 27706
Amy B. Summy officer: EVP, Chief Marketing Officer 531 SOUTH SPRING STREET, BURLINGTON NC 27215